EMULATE THERAPEUTICS, INC. Contracts & Agreements
33 Contracts & Agreements
- Business Finance (16 contracts)
- Business Operations (1)
- Human Resources (10)
- Intellectual Property (5)
- Uncategorized (1)
- Amended and Restated Employment Agreement between EMulate Therapeutics, Inc. and Kyle J. Kingma, effective as of October 1, 2023 (Filed With SEC on September 29, 2023)
- Amended and Restated Employment Agreement between EMulate Therapeutics, Inc. and Steven E. Pope, effective as of October 1, 2023 (Filed With SEC on September 29, 2023)
- Amended and Restated Employment Agreement between EMulate Therapeutics, Inc. and Chris E. Rivera, effective as of October 1, 2023 (Filed With SEC on September 29, 2023)
- Mutual General Release Agreement between the Company and John Butters and Lisa Butters (Filed With SEC on July 10, 2023)
- Consulting Agreement between the Company and West Boulder LLC (Filed With SEC on July 10, 2023)
- Form of Underwriting Agreement (Filed With SEC on January 26, 2023)
- Specimen certificate evidencing shares of Common Stock (Filed With SEC on January 26, 2023)
- Form of Representatives Warrant (Filed With SEC on January 26, 2023)
- Form of Representatives Warrant (Filed With SEC on January 4, 2023)
- Specimen certificate evidencing shares of Common Stock (Filed With SEC on January 4, 2023)
- Form of Underwriting Agreement (Filed With SEC on January 4, 2023)
- Convertible Note issued to John Kingma, dated February 5, 2021 (Filed With SEC on August 16, 2022)
- Convertible Note issued to Lucky Good Dog, LLC, dated July 20, 2021 (Filed With SEC on August 16, 2022)
- Convertible Note issued to Lucky Good Dog, LLC, dated February 23, 2021 (Filed With SEC on August 16, 2022)
- Convertible Note issued to John Kingma, dated January 31, 2021 (Filed With SEC on August 16, 2022)
- Convertible Note issued to John Kingma, dated February 5, 2021 (Filed With SEC on August 16, 2022)
- Convertible Note issued to John Kingma, dated February 5, 2021 (Filed With SEC on August 16, 2022)
- Distribution Agreement, dated October 10, 2019, by and between EMulate Therapeutics, Inc. and Sayre Therapeutics Private Limited (Filed With SEC on August 16, 2022)
- Promissory Note issued to John Kingma, dated July 15, 2021 (Filed With SEC on August 16, 2022)
- Promissory Note issued to John Kingma, dated July 6, 2021 (Filed With SEC on August 16, 2022)
- Promissory Note issued to Nancy Nordhoff, dated March 14, 2022 (Filed With SEC on August 16, 2022)
- Form of Stock Option Agreement for EMulate Therapeutics, Inc. 2016 Equity Incentive Plan (Filed With SEC on August 16, 2022)
- EMulate Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan (Filed With SEC on August 16, 2022)
- Amended and Restated Employment Agreement between EMulate Therapeutics, Inc. and Kyle J. Kingma, dated as of April 18, 2022 (Filed With SEC on August 16, 2022)
- Amended and Restated Employment Agreement between EMulate Therapeutics, Inc. and David C. Matteson, dated as of March 15, 2022 (Filed With SEC on August 16, 2022)
- Amended and Restated Employment Agreement between EMulate Therapeutics, Inc. and Steven E. Pope, dated as of March 15, 2022 (Filed With SEC on August 16, 2022)
- Amended and Restated Employment Agreement between EMulate Therapeutics, Inc. and Chris E. Rivera, dated as of March 15, 2022 (Filed With SEC on August 16, 2022)
- Right of First Refusal and Co-sale Agreement, dated March 22, 2002, by and between EMulate Therapeutics, Inc. and John T. Butters, Bennett M. Butters, and Lisa C. Butters (Filed With SEC on August 16, 2022)
- Amendment to Exclusive License Agreement, dated October 26, 2020, by and between EMulate Therapeutics, Inc. and Hapbee Technologies, Inc (Filed With SEC on August 16, 2022)
- Amended and Restated Exclusive License Agreement, dated October 26, 2020, by and between EMulate Therapeutics, Inc. and Hapbee Technologies, Inc (Filed With SEC on August 16, 2022)
- License Agreement, dated July 29, 2021, by and between EMulate Therapeutics, Inc. and Hapbee Technologies, Inc (Filed With SEC on August 16, 2022)
- Exclusive License Agreement, dated April 21, 2021, by and between EMulate Therapeutics, Inc. and Hapbee Technologies, Inc (Filed With SEC on August 16, 2022)
- Exclusive License Agreement, dated April 1, 2017, by and between EMulate Therapeutics, Inc. and Teijin Limited (Filed With SEC on August 16, 2022)
